KDMN Kadmon Holdings, Inc. Common St

+0  (2%)
Previous Close 2.47
Open 2.47
Price To book 0.00
Market Cap 130.13M
Shares 51,846,000
Volume 97,033
Short Ratio 6.01
Av. Daily Volume 213,466

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated mid-2017.
Autosomal dominant Polycystic Kidney Disease (ADPKD)
Phase 2 initiated September 2016. Data due 4Q 2017.
Chronic graft-versus-host disease (cGVHD)
Phase 2 data due 4Q 2017.
Idiopathic pulmonary fibrosis (IPF)
Phase 2 first patient dosed September 2016. Data due 4Q 2017.
Moderate to severe chronic plaque psoriasis
Phase 2 initiated August 2016
Recurrent glioblastoma - cancer
Phase 2 data on the first 13 patients to be presented at the IASLC 17th World Conference on Lung Cancer December 6 2016.
EGFR-mutant non-small cell lung cancer (NSCLC) that has metastasized to the brain

Latest News

  1. Kadmon Announces Publication of Clinical Data Showing KD025 Improved Clinical Scores in Psoriasis Patients
  2. Kadmon Submits Second Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA
  3. Kadmon Announces Amendment to Credit Agreement and Related Warrants
  4. ETFs with exposure to Kadmon Holdings, Inc. : March 30, 2017
  5. Kadmon Presents Preclinical Data Supporting the Therapeutic Potential of ROCK Inhibition in Pulmonary Fibrosis
  6. Kadmon Holdings, Inc. :KDMN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 24, 2017
  7. Kadmon Reports Upcoming Milestones and Fourth Quarter and Full Year 2016 Financial Results
  8. Kadmon Announces Approximately $23 Million Equity Financing
  9. Hedge Funds Are Buying Kadmon Holdings LLC (KDMN)
  10. Kadmon Presents Encouraging Data on Tesevatinib in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases and/or Leptomeningeal Metastases
  11. Kadmon Submits Abbreviated New Drug Application Filing for Trientine Hydrochloride to FDA
  12. Kadmon to Present at the 28th Annual Piper Jaffray Healthcare Conference
  13. Kadmon to Present at the Jefferies 2016 London Healthcare Conference
  14. Kadmon Provides Business Update and Reports Third Quarter 2016 Financial Results
  15. Kadmon to Present at the 15th Annual BIO Investor Forum
  16. Allergan's Vitae Buy Could Spark More Interest in Kadmon
  17. Kadmon Initiates Placebo-Controlled Phase 2 Clinical Trial Evaluating KD025 in Psoriasis
  18. Kadmon Initiates Phase 2 Clinical Trial Evaluating KD025 in Chronic Graft-Versus Host Disease
  19. Kadmon Reports Financial and Operational Results for the Three and Six Months Ended June 30, 2016
  20. Kadmon to Present at Two Upcoming Investor Conferences